Get started
Author

G. Scott Chandler

Observed names: Chandler GS, Chandler, G. Scott, G Scott Chandler, G. S. Chandler, G.S. Chandler
ORCID: 0000-0001-5339-9906
Observed ORCID: 0000-0001-5339-9906
OpenAlex ID: A5084564240
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
2020 · Zia Khan, Flavia Di Nucci, et al. · Proceedings of the National Academy of Sciences · 91
PDF
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
2021 · Zia Khan, Christian Hammer, et al. · Nature Communications · 87
PDF
Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
2019 · Zia Khan, Christian Hammer, et al. · Genome Medicine · 78
PDF
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
2025 · Chester Kao, Soren Charmsaz, et al. · Nature Communications · 37
PDF
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
2024 · Chester J. Kao, Soren Charmsaz, et al. · Journal of Clinical Investigation · 31
PDF
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
2025 · Stephanie L Alden, Soren Charmsaz, et al. · Journal for ImmunoTherapy of Cancer · 25
PDF
Baseline risk factors associated with immune related adverse events and atezolizumab
2023 · Katrin Madjar, Rajat Mohindra, et al. · Frontiers in Oncology · 21
Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing
2024 · Hannah Barman, Sriram Venkateswaran, et al. · JCO Clinical Cancer Informatics · 20
PDF
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy
2023 · Zia Khan, Min Jung, et al. · Genome Medicine · 19
PDF
irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets
2026 · Cosmin A. Bejan, Michelle Wang, et al. · EBioMedicine · 17
Correlation of safety and efficacy of atezolizumab therapy across indications
2024 · Gonzalo Durán-Pacheco, G Scott Chandler, et al. · Journal for ImmunoTherapy of Cancer · 10
PDF
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025 · Howard L. Li, Soren Charmsaz, et al. · Cancer Research Communications · 7
PDF
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
2025 · Mari Nakazawa, Soren Charmsaz, et al. · Cancer Immunology Research · 7
A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.
2011 · L. Naumovski, M. S. Gordon, et al. · Journal of Clinical Oncology · 5
Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors
2012 · Dejan Juric, Rodrigo Dienstmann, et al. · Cancer Research · 4
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
2025 · Chester J. Kao, Soren Charmsaz, et al. · Journal of Clinical Investigation · 3
The role of natural language processing techniques versus conventional methods to gain ICI safety insights from unstructured EHR data.
2023 · Matthew Stephen Block, Hannah Barman, et al. · JCO Global Oncology · 3
PDF
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma
2026 · Howard L Li, Soren Charmsaz, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
2023 · Aanika Balaji, Stephanie Leigh Alden, et al. · Journal of Clinical Oncology · 2
Hydrophobic complementarity-determining region 3 (CDR3) sequences elucidate the cardiotoxic effects of immune checkpoint inhibitors
2025 · Shoiab Bukhari, Rajat Mohindra, et al. · Research Square · 1
PDF
516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
2025 · Sunil Bhatt, Brian Henick, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Supplemental Table 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025 · Howard L. Li, Soren Charmsaz, et al. · 1
1178 Association between polygenic risk for thyroid dysfunction, derived from tumor panel sequencing, immune-related thyroid toxicity and overall survival in ICI treated NSCLC patients
2024 · Ericka Ebot, David Bray, et al. · Regular and Young Investigator Award Abstracts · 1
1173 Proteomic analysis in patients with immune checkpoint inhibitor (ICI) associated cardiotoxicity
2024 · Rajat Mohindra, Benjamin Fairfax, et al. · Regular and Young Investigator Award Abstracts · 1
Genetic drivers of severe skin toxicity with immune checkpoint inhibitors (ICIs) in Asian patients.
2024 · Kohei Yoshimine, Hiroki Goto, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 107
Citation count: 473
H-index: 10
I10-index: 11
Year
Topic
Type